image: Insilico Medicine founder and CEO Alex Zhavoronkov, PhD will discuss how artificial intelligence is transforming drug discovery as part of the World’s Top 50 Innovators, presented September 26-28 by Codex in London. view more
Credit: Insilico Medicine
Insilico Medicine founder and CEO Alex Zhavoronkov, PhD will speak as part of the World’s Top 50 Innovators, presented September 26-28 by Codex in London. The event features technology innovators — including scientists, engineers, entrepreneurs, and visionaries — who are addressing the world’s greatest challenges with bold ideas and breakthrough technologies.
The innovators will provide a 15-minute Codex Talk for the event sharing their expertise and predictions for the future. Zhavoronkov will be featured among a group of innovators in artificial intelligence (AI) and share insights into how AI is transforming drug discovery. Other innovators in the space include Caroline Gorski, CEO of R2 Factory at Rolls Royce; Daniel Nathrath, CEO of Ada Health, and Mark Warner, CEO of Faculty. There will also be a number of speakers focused on robotics, discussing its use in surgery, agriculture, and sustainable development.
With an end-to-end AI-driven drug discovery platform called Pharma.AI that will soon be supported by an AI-powered robotics lab, Insilico Medicine is utilizing technology to change the speed, efficiency and cost at which new drugs are produced. Drawing on trillions of data points, Insilico’s multi-part platform can quickly comb through data to discover novel targets for drugs (PandaOmics), design new molecules to fit those targets (Chemistry42), and predict the outcome of Phase 2 clinical trials (InClinico). The company has raised nearly $400 million in venture capital funding since it launched in 2014 and its lead AI-discovered and AI-designed drug for idiopathic pulmonary fibrosis is currently in Phase 1 trials, the first drug of its kind to reach this milestone. The Company has 30 additional drugs developed from its AI platform being advanced through its internal pipeline for indications including cancer, fibrosis, and COVID-19.
“We are shifting the paradigm for how drugs are produced,” says Insilico Medicine founder and CEO Alex Zhavoronkov. “I’m honored to share what we’ve learned in applying artificial intelligence and robotics to drug development and design as one of the World’s Top 50 Innovators. Current advances in technology have allowed us to completely reimagine how we can understand and treat disease and the more we share and collaborate, the faster we can move to improve human health.”
Zhavoronkov will speak on Mon., Sept. 26, 1:15-2:15pm London time, followed by a Q&A. The three-day event will be shown live at the Wellcome Collection museum in London. Swiss watchmaker Blancplain is the event’s Timekeeper and will provide timepieces as prizes for Best Codex Talk, Top Female Innovator, and Most Impactful Innovation.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.
For more information, visit www.insilico.com
For media inquiries, please contact media@insilicomedicine.com